Key Takeaways
- Growth engine reignited: Q4 revenue grew 14.2% vs IPM's 10.5%, snapping two sluggish quarters on pure MR productivity gains without adding headcount.
- Profitability outran revenue: FY26 net profit rose 19% before exceptionals on just 7% revenue growth, a leverage story built on cost discipline and an asset-light model.
- Capital return signals confidence: A ₹40 cr buyback at ₹250/share (no promoter participation) plus a 200% dividend, including a special component, were announced; management expects to recoup the cash within 12 months.
- Portfolio depth is the moat: Nine of the top 10 brands rank in the top five of their categories, and 92% of the portfolio sits outside NLEM, giving pricing power the industry average lacks.
- What to watch next quarter: Whether the promised second wave of first-in-India product launches materializes by May/June, the trajectory of the still work-in-progress Ortho franchise, and any inorganic move that deploys the cash chest.
Growth Recovery & Drivers
- Productivity-led, not headcount-led: Q4 growth came entirely from existing MRs; no new geographies or MRs were added, and management intends to keep it that way, extracting more from the same footprint to conserve cost.
- Volume and price both ahead: Volume growth of 2% beat the industry's near-flat 0.5%-1.3%, while price growth of 6.5%-7% ran a shade above the industry's ~5%, enabled by the 92% non-NLEM portfolio that permits up to 9.9% annual increases.
- New products need patience: New product contribution of 3%+ matched the industry, but management cautioned that establishing prescriptions across every pin code takes "possibly a year plus," so the FY26 launches are still building.
- Top 10 and tail grow together: The top 10 brands, at 58-60% of revenue, grew almost in line with the rest of the portfolio, with "hardly 1% change," signaling no concentration risk.
- Gynaec and Derma led: Growth was anchored by Gynaecology and Dermatology on strong prescription momentum; a few mature brands in select therapies moderated, but the high-growth segments more than offset the drag.
- Macro risk is external only: Management sees no demand impact from the Middle East situation, only some vendor-side packaging material cost pressure, which it considers absorbable given pharma's 65%-80% gross margins and the 10% allowed price increase.
Medhekar: "All the growth is completely strategic and structurally made in favor of yields. And I don't see any of the seasonal impact there."
Capital Allocation & Shareholder Returns
- Buyback and special dividend: A ₹40 cr buyback at ₹250 per share was announced March 12 with shareholder approval received April 27 and a May 4 record date; the board also recommended a 200% dividend including a one-time 75% special component, subject to AGM approval.
- Cash recoupment expected within a year: Management is "hopeful of recouping cash payout within next 12 months" and stated the current cash position is more than sufficient for any inorganic initiative.
- No fixed cash ceiling: When asked whether net cash is targeted below ₹200 crores, management said "I don't think we have a number in mind," pushing back on a specific threshold.
- Lean working capital is structural: Working capital has held at 11 days for two years, which management calls best-in-class and intends to maintain.
- Inorganic scouting continues: The board is guided by a capital allocation philosophy focused on disciplined value creation and improving ROCE/ROE, with access to bank finance now available to fund acquisitions if needed.
Gupta: "Keeping too much cash is also not productive, especially in the scenario of falling yields and also in a scenario wherein now we have access to bank finance to fund acquisitions."
Portfolio & Therapy Mix
- Gynaecology is the anchor: The portfolio is roughly half Gynaecology, 25% Ortho, and 10-15% Derma; Gynaec also carries the highest MR productivity, followed by Ortho and Derma.
- Ortho is the build story: Management described the third business as "work in progress" that will be built over the next couple of quarters, with all three franchises expected to "fire equally well" and contribute to profitable growth.
- Pricing power is structural: Price increases are SKU-based, taken when each SKU's 12-month period completes, with timing dependent on inventory levels and the need to trigger a purchase order.
- E-pharmacy is negligible: Revenue from e-pharmacies like Netmeds and 1mg is "almost insignificant" to mention, so the business remains firmly anchored in the traditional doctor-chemist channel.
- No anti-obesity exposure, no problem: Management asserted the portfolio is strong enough to beat the market and deliver 1.5x growth even without presence in the anti-obesity segment.
New Product Pipeline & Field Force
- Six launches, more coming: FY26 saw six new product launches and three SKU brand extensions; FY27 plans call for approximately 9-10 launches, half as brand extensions in legacy brands and 5-6 new products within the same three therapies.
- First-in-India second wave imminent: A second wave of a first-in-India product launch is being prepared, with molecules in Gynaecology, Ortho, and Derma, and an announcement expected by May end or June first week.
- MR upskilling underway: One upskilling workshop has been completed with product and therapy training for all MRs; the company follows a policy of internal promotions blended with external hiring when internal candidates are unavailable.
- Productivity figures withheld: Management declined to provide specific MR productivity numbers or a therapy-level growth breakdown when asked, citing offhand unavailability and, for salary hikes, the fact that appraisal cycles and KPI completions are not yet closed.
Medhekar: "New product establishment is a very, very hard work for prescriptions to start flowing in from each and every pin code of the country, which will take possibly a year plus for us to do that."
Cost Structure & Margin Levers
- Gross margins stable: Full-year gross margins were largely in line at 64.2%, with a minor 20-30 bps change attributed to product mix.
- No structural cost creep: The other-expenses increase of 30 bps was a timing issue, such as the scheduling of cycle meetings; beyond normal inflation, there is no structural increase in the cost base.
- CMO cost pass-through is staggered: Cost increases from CMOs are not passed on "as is" but absorbed over time in staggered fashion per purchase orders; management does not view these increases as permanent and expects them to fall when supply chains smoothen.
- Salary hike quantum undisclosed: Management declined to share the exact percentage of price hikes across the portfolio or the average salary hike for MRs, as appraisal cycles and KPI completions have not yet closed and will conclude possibly this quarter.
Gupta: "Pharmaceutical industry for growth is not capital intensive. It is brand intensive. And brand requires execution excellence at a field force level... By pumping in more working capital, I cannot grow the business."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Revenue growth | 1.5x IPM growth, translating to 12%-15% given IPM trending 6%-9% | FY27 |
| New product launches | Approximately 9-10 launches; half brand extensions, 5-6 new products in Gynaec/Ortho/Derma | FY27 |
| First-in-India product second wave | Announcement of molecules in Gynaecology, Ortho, Derma | By May end or June first week |
| Cash recoupment | Full recoupment of cash paid out via buyback and enhanced dividend | Within 12 months |
| MR headcount | No increase in MR or manager numbers; all growth from productivity improvement | Ongoing |
| Ortho franchise build-out | Built over next couple of quarters; all three franchises to "fire equally well" | Next few quarters |
Key Metrics
| Metric | Q4 FY26 |
|---|---|
| Revenue | ₹64 cr, +10% YoY |
| EBITDA | close to ₹11 cr, +9% YoY, margin close to 16% |
| PAT | close to ₹9 cr, +31% YoY, PAT margin approx. 14% |
| Revenue (full year FY26) | approx. ₹287 cr, approx. +7% YoY |
| EBITDA (full year FY26) | close to ₹61 cr, margin approx. 21% |
| Profit from operations (full year FY26) | close to ₹45 cr, +19% YoY, margin approx. 16% |
| Gross margin (full year FY26) | 64.2%, 20-30 bps change due to product mix |
| Cash position | upwards of ₹190 cr as on March 31 |
| Net working capital cycle | close to 11 days |
| MAT growth (Pharmarack) | 12.2%, outperforming market by 3.6% |
| Q4 growth (Pharmarack) | 14.2% against industry growth of 10.5% |
| Volume growth (Pharmarack, full year FY26) | 2% |
| Price growth (Pharmarack, full year FY26) | 6% to 7% |
| New product contribution to growth (Pharmarack, full year FY26) | 3.2% |
| Top 10 brands share of total sales | approx. 58% to 60% |
| Portfolio outside NLEM (price control) | 92% |
| Buyback | ₹40 cr at ₹250 per share, up to 16 lakh equity shares, no promoter participation |
| Dividend | 200% including one-time special dividend of 75%, total payout ₹4 per share, overall cash distribution approx. ₹26 cr |
| Total cash returned to shareholders (buyback + dividend) | over ₹66 cr |
| ROE post buyback | approx. 18%, up from approx. 16% |
| ROCE post buyback | close to 26%, up from approx. 22% |
| New product launches in FY26 | 6 new products and 3 SKUs (brand extensions) |
| Planned launches for FY27 | approx. 9 to 10, half brand extensions in legacy brands, 5-6 new products within same therapies |